氯吡格雷与丹参酮ⅡA磺酸钠注射液治疗急性脑梗死的临床效果
|
摘要
目的探讨急性脑梗死患者应用氯吡格雷与丹参酮ⅡA磺酸钠注射液治疗的临床效果。方法选取2017年3月至2018年12月于大石桥市中心医院接受治疗的126例急性脑梗死患者作为研究对象,将其随机分为对照组(应用氯吡格雷治疗,63例)与研究组(应用氯吡格雷联合丹参酮ⅡA磺酸钠注射液治疗,63例)。比较两组患者的临床疗效和神经功能恢复情况。结果研究组治疗有效率93.65%显著高于对照组的79.37%,差异有统计学意义(χ2=2.037,P=0.020<0.05);治疗前,研究组美国国立卫生研究院卒中量表(NIHSS)评分(12.6±6.2)分与对照组的(11.9±5.6)分比较,差异无统计学意义(t=0.665,P=0.507>0.05);治疗后,研究组NIHSS评分(5.1±6.3)分明显低于对照组的(7.9±7.4)分,差异有统计学意义(t=2.287,P=0.024<0.05)。结论急性脑梗死患者给予氯吡格雷联合丹参酮ⅡA磺酸钠注射液治疗效果明确,可有效改善患者神经功能,提高预后生命质量。
Objective To explore the clinical efficacy of clopidogrel combined with sodium tanshinone ⅡA sulfonate injection in patients with acute cerebral infarction. Methods A total of 126 patients with acute cerebral infarction treated in the Dashiqiao Central Hospital from March 2017 to December 2018 were selected as the study subjects. They were randomly divided into control group(63 cases, treated with clopidogrel) and study group(63 cases, treated with clopidogrel combined with sodium tanshinone ⅡA sulfonate injection). The clinical efficacy and neurological function recovery of the 2 groups were compared. Results The total effective rate of the study group(93.65%) was significantly higher than that of the control group(79.37%), and the difference was statistically significant(χ2=2.037, P=0.020<0.05). Before the treatment, the national institutes of health stroke scale(NIHSS) score of the study group(12.6±6.2) was similar to that of the control group(11.9±5.6), with no significant difference(t=0.665,P=0.507>0.05). After the treatment, the NIHSS score in the study group(5.1±6.3) was significantly lower than that in the control group(7.9±7.4), and the difference was statistically significant(t=2.287, P=0.024<0.05). Conclusion The curative effect of clopidogrel combined with sodium tanshinone ⅡA sulfonate injection in patients with acute cerebral infarction is definite. It can effectively improve the neurological function of patients, and improve the prognostic quality of life.
Objective To explore the clinical efficacy of clopidogrel combined with sodium tanshinone ⅡA sulfonate injection in patients with acute cerebral infarction. Methods A total of 126 patients with acute cerebral infarction treated in the Dashiqiao Central Hospital from March 2017 to December 2018 were selected as the study subjects. They were randomly divided into control group(63 cases, treated with clopidogrel) and study group(63 cases, treated with clopidogrel combined with sodium tanshinone ⅡA sulfonate injection). The clinical efficacy and neurological function recovery of the 2 groups were compared. Results The total effective rate of the study group(93.65%) was significantly higher than that of the control group(79.37%), and the difference was statistically significant(χ2=2.037, P=0.020<0.05). Before the treatment, the national institutes of health stroke scale(NIHSS) score of the study group(12.6±6.2) was similar to that of the control group(11.9±5.6), with no significant difference(t=0.665,P=0.507>0.05). After the treatment, the NIHSS score in the study group(5.1±6.3) was significantly lower than that in the control group(7.9±7.4), and the difference was statistically significant(t=2.287, P=0.024<0.05). Conclusion The curative effect of clopidogrel combined with sodium tanshinone ⅡA sulfonate injection in patients with acute cerebral infarction is definite. It can effectively improve the neurological function of patients, and improve the prognostic quality of life.
引文
[1]梁鑫,夏春义,傅志坚,等.丹参酮ⅡA磺酸钠对急性脑梗死病人血清TNF-αCRP和神经功能缺损程度评分的影响[J].中国实用乡村医生杂志, 2016, 23(3):68-69.
[2]姜长春,李月春,王宝军,等.动脉溶栓和动静脉联合溶栓及机械取栓治疗急性脑梗死的比较研究[J].中华老年心脑血管病杂志, 2013, 15(1):60-63.
[3]张静静,吕荣祥,刘郁,等.老年急性脑梗死患者血尿酸、凝血功能、炎症因子和血液流变学指标的变化[J].中国老年学杂志,2018, 38(8):1815-1817.
[4]中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43(2):146-153.
[5]佘彬彬.MRA在脑梗死诊断和治疗中的价值[J].中国处方药,2018, 16(2):136-137.
[6]张娣,张培功,姜兴岳,等.脑梗死扩散峰度成像的时间进程分析及其与扩散张量成像的对比研究[J].中国医学影像技术,2017, 33(5):683-687.
[7]杨梅,蒲晓,张倩,等.丁苯酞氯化钠、脑心通胶囊联合丹参酮ⅡA磺酸钠治疗急性缺血性脑卒中的临床效果及对炎性因子的影响[J].临床和实验医学杂志, 2018, 17(2):148-151.
[8]王大庆.脑心通胶囊对急性缺血性脑卒中恢复期运动功能和D-二聚体、血小板聚集率的影响[J].社区医学杂志, 2017, 15(9):21-23.
[9]吴晖,陈新利,耿华,等.氯吡格雷活性代谢物在人体内的血药浓度测定[J].中国医院药学杂志, 2017, 37(11):1065-1068.
[10]林春.负荷剂量氯吡格雷在急性脑梗死早期治疗中的应用[J].医学理论与实践, 2018, 31(3):357-358.
[11]徐丙超,周芯羽,王轩,等.丹参酮ⅡA磺酸钠注射液治疗急性脑梗死的临床研究[J].中国药房, 2017, 28(26):3660-3663.
[12]刘家军,吴松,李龙珠,等.丹参酮ⅡA磺酸钠注射液对兔心肌缺血预处理后血管内皮损伤的保护作用[J].世界中医药,2017,12(3):618-622.
[2]姜长春,李月春,王宝军,等.动脉溶栓和动静脉联合溶栓及机械取栓治疗急性脑梗死的比较研究[J].中华老年心脑血管病杂志, 2013, 15(1):60-63.
[3]张静静,吕荣祥,刘郁,等.老年急性脑梗死患者血尿酸、凝血功能、炎症因子和血液流变学指标的变化[J].中国老年学杂志,2018, 38(8):1815-1817.
[4]中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43(2):146-153.
[5]佘彬彬.MRA在脑梗死诊断和治疗中的价值[J].中国处方药,2018, 16(2):136-137.
[6]张娣,张培功,姜兴岳,等.脑梗死扩散峰度成像的时间进程分析及其与扩散张量成像的对比研究[J].中国医学影像技术,2017, 33(5):683-687.
[7]杨梅,蒲晓,张倩,等.丁苯酞氯化钠、脑心通胶囊联合丹参酮ⅡA磺酸钠治疗急性缺血性脑卒中的临床效果及对炎性因子的影响[J].临床和实验医学杂志, 2018, 17(2):148-151.
[8]王大庆.脑心通胶囊对急性缺血性脑卒中恢复期运动功能和D-二聚体、血小板聚集率的影响[J].社区医学杂志, 2017, 15(9):21-23.
[9]吴晖,陈新利,耿华,等.氯吡格雷活性代谢物在人体内的血药浓度测定[J].中国医院药学杂志, 2017, 37(11):1065-1068.
[10]林春.负荷剂量氯吡格雷在急性脑梗死早期治疗中的应用[J].医学理论与实践, 2018, 31(3):357-358.
[11]徐丙超,周芯羽,王轩,等.丹参酮ⅡA磺酸钠注射液治疗急性脑梗死的临床研究[J].中国药房, 2017, 28(26):3660-3663.
[12]刘家军,吴松,李龙珠,等.丹参酮ⅡA磺酸钠注射液对兔心肌缺血预处理后血管内皮损伤的保护作用[J].世界中医药,2017,12(3):618-622.